HedgeChatter

  • Home /
  • Tag Archives

ITMN

InterMune slips off lofty perch while Aegerion’s earnings disappoint

[at MarketWatch] – Two drug makers, InterMune Inc. and Aegerion Pharmaceuticals, drop by double digits early in Wednesday’s trading. moreView todays social media effects on ITMNView the latest stocks trending across Twitter. Click to view dashboardSee who InterMune is hiring next, click here to view […]

February 26, 2014 Bystocknews , Comments Off on InterMune slips off lofty perch while Aegerion’s earnings disappoint read more

InterMune Inc. ASCENDs to Greatness

moreView todays social media effects on ITMNView the latest stocks trending across Twitter. Click to view dashboardSee who InterMune is hiring next, click here to view […]

February 26, 2014 Bystocknews , Comments Off on InterMune Inc. ASCENDs to Greatness read more

InterMune hits 2-year high on US Esbriet study

moreView todays social media effects on ITMNView the latest stocks trending across Twitter. Click to view dashboardSee who InterMune is hiring next, click here to view […]

February 25, 2014 Bystocknews , Comments Off on InterMune hits 2-year high on US Esbriet study read more

InterMune Stock Doubles As Drug Fights Lung Disease

moreView todays social media effects on ITMNView the latest stocks trending across Twitter. Click to view dashboardSee who InterMune is hiring next, click here to view […]

February 25, 2014 Bystocknews , Comments Off on InterMune Stock Doubles As Drug Fights Lung Disease read more

9:22 am InterMune trades up 161% to $36.40 in pre-market following resumption of trading. Co reported positive Phase 3 ASCEND trial results of pirfenidone in idiopathic pulmonary fibrosis

moreView todays social media effects on ITMNView the latest stocks trending across Twitter. Click to view dashboardSee who InterMune is hiring next, click here to view […]

February 25, 2014 Bystocknews , Comments Off on 9:22 am InterMune trades up 161% to $36.40 in pre-market following resumption of trading. Co reported positive Phase 3 ASCEND trial results of pirfenidone in idiopathic pulmonary fibrosis read more

InterMune pirfenidone data near best-case, says UBS

moreView todays social media effects on ITMNView the latest stocks trending across Twitter. Click to view dashboardSee who InterMune is hiring next, click here to view […]

February 25, 2014 Bystocknews , Comments Off on InterMune pirfenidone data near best-case, says UBS read more